A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising ...

The U.S. Food and Drug Administration declined to approve Atara Biotherapeutics' cell therapy for a rare form of blood cancer ...

Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted ...

Patients treated in an outpatient setting who later required admission spent an average of 12.1 days in the hospital, ...

Cellares and City of Hope are partnering to evaluate automating CAR T manufacturing for glioblastoma brain cancer therapy.

Liu described the CAR-like T cells as cytokine-activated lymphocytes engineered with the tumor-targeting and -penetrating ...

Orca Bio has disclosed $250 million in funding, flooding its balance sheet with cash to buoy preparations for the ...

A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living ...

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...

Cargo Therapeutics, a developer of cell therapies intended to overcome cancer mechanisms that lead to relapse, is stopping its lead program after a safety complication emerged in a clinical trial that ...

The EVEREST-2 study reported the first complete response to CAR-T cell therapy in a non-small cell lung cancer patient.